Compare ZYXI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZYXI | CLLS |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8M | 299.0M |
| IPO Year | N/A | 2007 |
| Metric | ZYXI | CLLS |
|---|---|---|
| Price | $0.26 | $4.18 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $3.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 10.1M | 132.4K |
| Earning Date | 11-17-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $108,202,000.00 | $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | $9.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $0.23 | $1.10 |
| 52 Week High | $8.72 | $5.48 |
| Indicator | ZYXI | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 33.57 | 48.01 |
| Support Level | $0.23 | $4.47 |
| Resistance Level | $0.95 | $5.45 |
| Average True Range (ATR) | 0.14 | 0.29 |
| MACD | -0.07 | -0.12 |
| Stochastic Oscillator | 6.61 | 25.97 |
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.